January 03, 2011

Immunoantibiotics: Vaccine Platform Holds Great Promise

By Tom O'Connor, UNMC public relations

Tamsin Sheen, Kelly Doran, Ed Morgan, and Sam Sanderson
Tamsin Sheen, Kelly Doran, Ed Morgan, and Sam Sanderson

Thanks to the vaccine platform technology invented by a collaborative SDSU / UNMC research team, a new generation of vaccines and therapies could be in the works for viral, bacterial and fungal infections as well as several forms of cancer.

The research, which was done on laboratory mice in collaboration with a research team from San Diego State University, also shows promise for generating better immune response in the elderly, a group that is normally not responsive to traditional vaccines. The research appears in the December issue of Vaccine, a leading science journal in the vaccine field.

"Now that we have the platform developed, the vaccine applications are almost limitless," said Sam Sanderson, Ph.D., associate professor in the UNMC School of Allied Health Professions and the lead investigator on the vaccine platform. The platform technology involves a small structurally engineered peptide known as EP67. The researchers found that effective vaccines could be made by attaching EP67 to an antigen, the entity that researchers want the immune system to rise up against.


View Journal Article┬╗